Filing Details
- Accession Number:
- 0000014272-15-000214
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-08-05 16:57:22
- Reporting Period:
- 2015-08-03
- Filing Date:
- 2015-08-05
- Accepted Time:
- 2015-08-05 16:57:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 14272 | Bristol Myers Squibb Co | BMY | Pharmaceutical Preparations (2834) | 220790350 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1208099 | Lamberto Andreotti | Bristol-Myers Squibb Company 345 Park Avenue New York NY 10154 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.10 Par Value | Acquisiton | 2015-08-03 | 115,000 | $22.73 | 685,074 | No | 4 | M | Direct | |
| Common Stock, $0.10 Par Value | Acquisiton | 2015-08-03 | 200,000 | $24.74 | 885,074 | No | 4 | M | Direct | |
| Common Stock, $0.10 Par Value | Disposition | 2015-08-03 | 31,200 | $64.75 | 853,874 | No | 4 | S | Direct | |
| Common Stock, $0.10 Par Value | Disposition | 2015-08-03 | 283,800 | $65.43 | 570,074 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock, $0.10 Par Value | Option (right to buy) | Disposition | 2015-08-03 | 115,000 | $0.00 | 115,000 | $22.73 |
| Common Stock, $0.10 Par Value | Option (right to buy) | Disposition | 2015-08-03 | 200,000 | $0.00 | 200,000 | $24.74 |
| Common Stock, $0.10 Par Value | Deferred Share Units | Acquisiton | 2015-08-03 | 1,211 | $65.34 | 1,211 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-03-06 | No | 4 | M | Direct | |
| 100,000 | 2016-11-30 | No | 4 | M | Direct | |
| 1,211 | No | 4 | A | Direct |
Footnotes
- A portion of these shares were sold to cover exercise price and taxes in accordance with broker's procedure for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $64.69 to $64.81, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- A portion of these shares were sold to cover exercise price and taxes in accordance with broker's procedure for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $65.00 to $65.78, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 7, 2006.
- One-third of the stock option award vested on each of the third, fourth, and fifth anniversaries of the grant date, which was December 1, 2006.
- Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- Represents pro rata portion of the 2015 annual Deferred Share Units awards granted to the Company's directors.
Billionaire Hedge Funds
